Zokinvy Capsule
NDC Package 42358-475-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Zokinvy (lonafarnib) capsules is zOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either:Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations. This formulation utilizes a capsule delivery system. Marketed by Sentynl Therapeutics, Inc., this product is identified by NDC 42358-475 and is authorized under FDA application NDA213969.

Identification & Billing

NDC Package Code
42358-475-30
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 30 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
42358-475
11-Digit Billing Format
42358047530
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zokinvy
Non-Proprietary Name
Lonafarnib
Substance Name
Lonafarnib
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
LONAFARNIB 75 mg/1
Pharmacologic Class
Usage Information
ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either:Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations

Regulatory & Marketing

Labeler Name
Sentynl Therapeutics, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA213969
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-02-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42358-475-30 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 30 capsule in 1 bottle, plastic of Zokinvy, a human prescription drug labeled by Sentynl Therapeutics, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This capsule is formulated for oral use and contains lonafarnib as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sentynl Therapeutics, Inc. on July 02, 2025. The current certification is valid through December 31, 2027.

How is this Sentynl Therapeutics, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42358047530. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42358-475-30
11-Digit CMS (5-4-2)
42358-0475-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.